Aficamten (previously CK-3773274; CK-274) is an orally bioavailable cardiac myosin inhibitor with the potential for treating Hypertrophic Cardiomyopathy (HCM). On Dec 10, 2021, FDA has granted breakthrough therapy designation for aficamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy. Hypercontractility of the cardiac sarcomere may be essential for the underlying pathological hypertrophy and fibrosis in genetic hypertrophic cardiomyopathies.

纯度：≥98%

CAS：2364554-48-1